Search PubMed⌕ Search

PubMed · 6502149

Cognitive style, cortical function, and electroconvulsive therapy.

Abstract

Performance on the rod and frame test (RFT) was measured over three separate occasions in three groups of 20 depressive patients and a nonpatient control group. Depressive patients were selected into three groups according to whether they had been prescribed one of three forms of treatment: bilateral electroconvulsive therapy (ECT), nondominant unilateral ECT, or a course of antidepressant drugs. The RFT was administered on three occasions: before treatment, 1 week after completion of treatment, and at 3 months follow-up. The control group received no treatment, but were tested at comparable periods. The RFT was scored as mean absolute error and also as separate frame-dependent, rod-dependent, and constant error components. All depressive groups showed improved error measures post-treatment. The two ECT groups showed less frame dependence post-treatment than the drug group. The group receiving bilateral ECT showed a greater decrease in the mean error of performance than the unilateral group. Right-sided unilateral ECT affected frame dependence in patients who were initially frame independent, rather than in those who were initially frame dependent. The results indicated that the effect of ECT may depend on a patient's initial pretreatment cognitive style.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K P O'Connor, N Colter, J C Shaw. 1984. Cognitive style, cortical function, and electroconvulsive therapy.. https://doi.org/10.1097/00005053-198412000-00003

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring.

Therapeutic drug monitoring necessitates efficient, fast and reliable analytical methods validated by external quality control. We therefore devised an isocratic reversed-phase HPLC method with ultraviolet detection and optimised this to quantify mirtazapine, reboxetine, moclobemide, venlafaxine, O-desmethylvenlafaxine, paroxetine, fluvoxamine, fluoxetine, norfluoxetine, sertraline, citalopram, amitriptyline, nortriptyline, imipramine, desipramine, doxepin, nordoxepin, clomipramine, norclomipramine, trimipramine, mianserine, maprotiline, normaprotiline, amisulpride, clozapine, norclozapine, quetiapine, risperidone and 9-OH-risperidone in human serum. After solid-phase extraction of the drugs and metabolites, the chromatographic separation was achieved on a Nucleosil 100-Protect 1 column with acetonitrile-potassium dihydrogenphosphate buffer as mobile phase. The method was validated for therapeutic and toxic serum ranges. A linear relationship (r>0.998) was obtained between the concentration and the detector signal. Recoveries were between 75 and 99% for the drugs and metabolites. The accuracy of the quality control samples, expressed as percent recovery, ranged from 91 to 118%; intra- and inter-assay-relative standard deviations were 0.9-10.2% and 0.9-9.7%, respectively. Additional external quality control is carried out since 3 years. This method is applicable to rapidly and effectively analyze serum or plasma samples for therapeutic drug monitoring of about 30 antidepressants and atypical antipsychotics.

Antidepressive Agents↗